ethyl 3-phenylpropanimidate | 13226-93-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-phenylpropanimidate
• 英文别名: 3-phenyl-propionimidic acid ethyl ester；3-Phenyl-propionimidsaeure-aethylester；Hydrozimtsaeure-iminoaethylaether；3-Phenylpropionimidic acid ethyl ester
• CAS: 13226-93-2
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: BBTZTVGXKNYWHY-UHFFFAOYSA-N

物化性质

• 沸点：
  129.5-130 °C
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 3-phenylpropanimidate 在 氨 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 3-phenylpropionamidine
  参考文献：
  名称：

  Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors

  摘要：

  The synthesis and biological evaluation of novel human A-FABP inhibitors based on the 6-(trifluoromethyl)pyrimidine-4(1H)-one scaffold is described. Two series of compounds, bearing either an amino or carbon substituent in the 2-position of the pyrimidine ring were investigated. Modification of substituents and chain length optimization led to novel compounds with low micromolar activity and good selectivity for human A-FABP. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.058
• 作为产物：
  描述：

  ethyl 3-phenylpropionimidate hydrochloride 在 potassium carbonate 作用下， 以 水 为溶剂， 生成 ethyl 3-phenylpropanimidate
  参考文献：
  名称：

  Convenient Synthesis of 5-Substituted 2-Amino[1,2,4]triazolo[1,5- a][1,3,5]triazin-7(6H)-ones from N-Triazolide Imidates and 1,2,4-Triazole-3,5-diamine

  摘要：

  报道了一种方便高效的制备先前未报道的N-三唑酸亚胺的方法及其与1,2,4-三唑-3,5-二胺的反应，该反应可区域选择性地生成5-取代的2-氨基[1,2,4]三唑并[1,5-a][1,3,5]三嗪-7(6H)-酮。通过X射线晶体学，已明确证实了所报道的双环化合物的结构。

  DOI：

  10.1055/s-0029-1218718

文献信息

• AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Ji YuHua

  公开号：US20090170870A1

  公开（公告）日：2009-07-02

  The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, where R 1-3 , R 5 , R 7 , a, b, Q, X, X′, X″, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

  该发明涉及以下式I的化合物：或其药用可接受的盐，其中R1-3、R5、R7、a、b、Q、X、X′、X″、Y、Z和Ar如规范中所定义。这些化合物是肌肉胆碱受体拮抗剂。该发明还涉及含有这些化合物的药物组合物，制备这些化合物的方法以及利用这些化合物治疗肺部疾病（如慢性阻塞性肺疾病和哮喘）等方法。
• Copper(II)-Catalyzed Benzylic C(sp³)–H Aerobic Oxidation of (Hetero)Aryl Acetimidates: Synthesis of Aryl-α-ketoesters
  作者：Yogesh Kumar、Yogesh Jaiswal、Amit Kumar

  DOI：10.1021/acs.joc.6b02176

  日期：2016.12.16

  straightforward method is developed in this paper for the synthesis of α-ketoesters through copper-catalyzed aerobic oxidation of (hetero)aryl acetimidates using molecular oxygen as a sustainable oxidant. The reaction represents the first example of the direct synthesis of aryl-α-ketoesters from arylacetimidates through the aerobic oxidation of a benzylic C(sp3)–H (C═O) bond in moderate to good yield. This transformation

  本文开发了一种简单的方法，使用分子氧作为可持续的氧化剂，通过铜催化的（杂）芳基乙酰亚氨酸的需氧氧化，合成α-酮酸酯。该反应代表了通过对苄基C （sp3） -H（C═O）键进行有氧氧化以中等至良好收率，由芳基乙酰亚氨酸酯直接合成芳基-α-酮酸酯的第一个例子。这种转化在温和的反应条件下与多种底物一起发生，并利用了容易获得的氧化剂和催化剂。这种转化的合成效用通过放大合成得到了证明。还提出了合理的反应机理。
• [EN] CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIMIDONE INHIBANT LA CGAS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021233852A1

  公开（公告）日：2021-11-25

  The invention relates to a compound of formula (I), wherein R1-R3 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  该发明涉及一种化合物，其化学式为(I)，其中R1-R3和A1-A3如描述和索赔中所定义。化合物的化学式(I)可用作药物。
• [EN] PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] DÉRIVÉS DE PYRIDINONE ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011076687A1

  公开（公告）日：2011-06-30

  Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related conditions in both men and women, as well as a mammal in general (also referred to herein as a "subject"). For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, heavy menstrual bleeding, particularly menorrahagia and dysmenorrehea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to pyridinone derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  吡啶酮衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于制造用于治疗和/或预防疾病的药物的用途，特别是用于男性和女性的性激素相关疾病，以及一般哺乳动物（在本文中也称为“受试者”）。例如，这些疾病包括子宫内膜异位症、子宫肌瘤、多囊卵巢综合征、月经过多出血，尤其是月经过多和月经痛、多毛症、早熟、依赖性生殖腺类固醇的肿瘤，如前列腺、乳腺和卵巢癌、性腺激素释放激素依赖性垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕（例如，辅助生殖疗法，如体外受精）。本申请特别涉及吡啶酮衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂。
• Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
  申请人：Doronina Svetlana O.

  公开号：US20090111756A1

  公开（公告）日：2009-04-30

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

  具有C-末端苯丙氨酸羧基酸等效物的MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物已经制备，并通过各种连接剂（包括maleimidocaproyl-val-cit-PAB）连接到配体上。 结果得到的配体药物结合物在体外和体内均具有活性。